DRKS00017553RecruitingPhase 2
Renoprotection for TAVI-Patients with renal dysfunction through remote ischemic preconditioning (rIPC) - RenTAVI
niversitätsmedizin Rostock, Zentrum für Innere Medizin, Abteilung Kardiologie0 sites100 target enrollmentStarted: March 2, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled study
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •transcatheter aortic valve Implantation (TAVI), renal dysfunction defined as Serum creatinine >123,76 µmol/l or GFR <60 ml/min/1,73m² calculated with CKD-EPI formula, informed consent
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Terminated
Phase 3
Venous Thromboembolism in Renally Impaired Patients and Direct Oral AnticoagulantsRenal InsufficiencyNCT02664155Centre Hospitalier Universitaire de Saint Etienne203
Completed
Not Applicable
Perioperative renal protection in patients subject to cardio-pulmonary bypassCardiopulmonary bypassSurgeryISRCTN66959365Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)80
Completed
Phase 4
The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During TAVIRadiographic Contrast Agent NephropathyAortic Valve Stenosis With InsufficiencyNCT01866800Tel-Aviv Sourasky Medical Center136
Unknown
Not Applicable
Transcatheter Implantation of Aortic Bioprosthesis Without the Use of Iodinated Contrast in Patients With Chronic Kidney DiseaseRenal InsufficiencyValve StenosisRenal FailureNCT04581694University of Sao Paulo General Hospital75
Withdrawn
Phase 4
The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot StudyHeart FailureNCT01663662University of Michigan